Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and to improve biodefense. Its lead product candidate is TNX-102 SL or Tonmya that is designed as a bedtime administration for posttraumatic stress disorder (PTSD), which is in Phase 3 study in the military-related PTSD population. The company is also developing TNX-601 (tianeptine oxalate), a pre-investigational new drug (pre-IND) application stage, designed as a daytime administration for the treatment of PTSD; and TNX-801, a live synthetic version of horsepox virus at the pre-IND application stage. Its product pipeline also includes TNX-301, a potential treatment for AUD; and TNX-701, a biodefense development program for protection from radiation injury. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TNXP
CUSIPN/A
Phone212-980-9155
Debt
Debt-to-Equity RatioN/A
Current Ratio7.23
Quick Ratio7.23
Price-To-Earnings
Trailing P/E Ratio-0.22
Forward P/E Ratio-0.27
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.16 per share
Price / Book0.20
Profitability
EPS (Most Recent Fiscal Year)($2.90)
Net Income$-21,120,000.00
Net MarginsN/A
Return on Equity-107.17%
Return on Assets-97.33%
Miscellaneous
Employees14
Outstanding Shares10,020,000
Market Cap$6.65 million
Tonix Pharmaceuticals (NASDAQ:TNXP) Frequently Asked Questions
What is Tonix Pharmaceuticals' stock symbol?
Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."
How were Tonix Pharmaceuticals' earnings last quarter?
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) posted its earnings results on Monday, August, 13th. The company reported ($0.73) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.76) by $0.03. View Tonix Pharmaceuticals' Earnings History.
When is Tonix Pharmaceuticals' next earnings date?
What price target have analysts set for TNXP?
5 equities research analysts have issued 12 month target prices for Tonix Pharmaceuticals' shares. Their predictions range from $1.00 to $8.00. On average, they anticipate Tonix Pharmaceuticals' stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 599.4% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.
What is the consensus analysts' recommendation for Tonix Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Tonix Pharmaceuticals.
Are investors shorting Tonix Pharmaceuticals?
Tonix Pharmaceuticals saw a drop in short interest during the month of August. As of August 15th, there was short interest totalling 206,888 shares, a drop of 58.6% from the July 31st total of 500,326 shares. Based on an average daily volume of 474,090 shares, the days-to-cover ratio is currently 0.4 days. Approximately 2.7% of the shares of the company are short sold. View Tonix Pharmaceuticals' Current Options Chain.
Who are some of Tonix Pharmaceuticals' key competitors?
Some companies that are related to Tonix Pharmaceuticals include BENITEC BIOPHAR/S (BNTC), Citius Pharmaceuticals (CTXR), OvaScience (OVAS), Soligenix (SNGX), Sernova (SEOVF), Innovus Pharmaceuticals (INNV), Akari Therapeutics (AKTX), X T L Biopharmaceuticals (XTLB), Nuvo Pharmaceuticals (NRIFF), NeuroVive Pharmaceutical (NEVPF), Xenetic Biosciences (XBIO), RegeneRx Biopharmaceuticals (RGRX), Edge Therapeutics (EDGE), Midatech Pharma (MTP) and Diffusion Pharmaceuticals (DFFN).
Who are Tonix Pharmaceuticals' key executives?
Tonix Pharmaceuticals' management team includes the folowing people:
- Dr. Seth Lederman, Co-Founder, Pres, CEO & Chairman (Age 60)
- Dr. Donald W. Landry, Co-Founder & Director (Age 63)
- Mr. Bradley Saenger, CFO & Treasurer (Age 44)
- Dr. Gregory M. Sullivan, Chief Medical Officer & Sec. (Age 52)
- Mrs. Jessica Edgar Morris, Chief Operating Officer
Who are Tonix Pharmaceuticals' major shareholders?
Tonix Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.15%). Company insiders that own Tonix Pharmaceuticals stock include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.
Which major investors are buying Tonix Pharmaceuticals stock?
TNXP stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Tonix Pharmaceuticals stock in the last two years include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Insider Buying and Selling for Tonix Pharmaceuticals.
How do I buy shares of Tonix Pharmaceuticals?
Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tonix Pharmaceuticals' stock price today?
One share of TNXP stock can currently be purchased for approximately $0.6434.
How big of a company is Tonix Pharmaceuticals?
Tonix Pharmaceuticals has a market capitalization of $6.65 million. The company earns $-21,120,000.00 in net income (profit) each year or ($2.90) on an earnings per share basis. Tonix Pharmaceuticals employs 14 workers across the globe.
What is Tonix Pharmaceuticals' official website?
How can I contact Tonix Pharmaceuticals?
Tonix Pharmaceuticals' mailing address is 509 MADISON AVE. - SUITE 306, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]
MarketBeat Community Rating for Tonix Pharmaceuticals (NASDAQ TNXP)
MarketBeat's community ratings are surveys of what our community members think about Tonix Pharmaceuticals and other stocks. Vote "Outperform" if you believe TNXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TNXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
